MedPath

Rheos(TM) Pivotal Trial, a Study of Baroreflex Hypertension Therapy in Refractory Hypertension. Amendment 1: Dynamic cerebral autoregulation and lacol pulsewave velocity. Amendment 2: Investigational Plan , revision D Amendment 3: Investigational Plan, revision E Amendment 4: Investigational Plan, revision F

Phase 3
Completed
Conditions
refractory high blood pressure
therapy-resistent hypertension
10057166
Registration Number
NL-OMON38362
Lead Sponsor
CVRx Inc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
16
Inclusion Criteria

Ten minste 21 jaar en niet ouder dan 80 jaar
Office blood pressure equal or above 160/80 mmHg
Ambulatory 24-hour systolic blood pressure equal or above 135 mmHg
Normal anatomy of carotid artery bifurcations
Full doses of anti-hypertensive treatment (3 medication with 1 diuretic)
Compliant to therapy
Not pregnant or contemplating pregnancy during study period

Exclusion Criteria

Known or suspected baroreflex failure or autonomic neuropathy
Body Mass Index above 45
Myocardial infarction, unstable angina, syncope or CVA within the past 3 months
Carotid atherosclerosis producing a 50% or greater reduction in diameter
Prior surgery, radiation or endobvascular stent placement in carotid sinus region
Severe chronic kidney disease, estimated GFR below 30 ml/min

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath